Diagnostic solutions for precision oncology

Personalised precision medicine has become a new paradigm in oncology treatment, offering hope for improved cancer treatments. Advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing (NGS) allow clinicians and laboratory professionals to routinely gather therapy-relevant molecular information in a timely fashion, a condition that is required for true personalized medicine in the face of a growing list of molecularly targeted drugs*.

Thermo Fisher Scientific offers multiple solutions for solid tumor biomarker testing to aid in identifying those patients eligible for treatment, based on Ion Torrent and Oncomine NGS technology.

As IVD regulations and oncology drug and testing market needs are different in countries and regions around the world, we offer the following localized solutions:

Oncomine Dx Target Test (US only)

The Oncomine Dx Target Test is the first FDA-approved test that can detect multiple gene mutations for NSCLC in a single test from a single tissue sample, simultaneously delivering multiple biomarker results from one sample within four days. The Oncomine Dx  Target Test has been approved by the FDA as a companion diagnostic to aid in the selection of NSCLC patients for treatment with specific targeted therapies,The Oncomine Dx Target Test will be available in July 2017 in the United States only. We are currently working on making it available in other countries. Details to be announced at a later date.

Oncomine Solid Tumor kits (Europe only)

The Oncomine Solid Tumor DNA Kit and Oncomine Solid Tumor Fusion Transcript Kit are targeted NGS-based kits that enable the detection of multiple solid tumor DNA- and RNA-based biomarkers, including EGFR, BRAF, ALK, ROS1, KRAS, and NRAS.  These kits can be used separately or together in a single workflow and offer a flexible solution for the preparation of targeted libraries for the detection of multiple actionable solid tumor biomarkers, particularly for NSCLC, colon cancer, and melanoma.

*Scientific Advances in Lung Cancer; 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.